Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase

Clinical Cancer Research

Volumn 4, Issue 12, 1998, Pages 3089-3094

  Guichard, Sylvie M ^a   Morton, Christopher L ^a   Krull, Erik J ^a   Stewart, Clinton F ^a   Danks, Mary K ^a   Potter, Philip M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG DETERMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER METABOLISM; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CELL DIVISION; CULTURE MEDIA; HUMANS; LIVER; MASS SPECTROMETRY; RABBITS; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0032440452     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lokiec, F., Monegier du Sorbier, B., and Sanderink, G. Irinotecan (CPT-11) metabolites in human bile and urine. Clin. Cancer Res., 2: 1943-1949, 1996.
2. Rivory, L. P., Riou, J. F., Haaz, M. C., Sable, S., Vuilhorgne, M., Commercon, A., Pond, S. M., and Robert, J. Identification and properties of a major plasma metabolite of irinotecan (CPT11) isolated from the plasma of patients. Cancer Res., 56: 3689-3694, 1996.
3. Rivory, L. P., Bowles, M. R., Robert, J., and Pond, S. M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol., 52: 1103-1111, 1996.
4. Kojima, A., Hackett, N. R., Ohwada, A., and Crystal, R. G. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J. Clin. Invest., 101: 1789-1796, 1998.
5. Rivory, L., Haaz, M., Canal, P., Lokiee, F., Armand, J., and Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin. Cancer Res., 3: 1261-1266, 1997.
6. Haaz, M., Rivory, L., Riche, C., Vemillet, L., and Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P450 3A and drug interactions. Cancer Res., 58: 468-472, 1998.
7. Chabot, G. G. Clinical pharmacokinetics of irinotecan. Clin. Pharmacokinet., 33: 245-259, 1997.
8. Mentlein, R., and Heymann, E. Hydrolysis of ester- and amide-type drugs by the purified isoenzymes of nonspecific carboxylesterase from rat liver. Biochem. Pharmacol., 33: 1243-1248, 1984.
9. Hosokawa, M., Maki, T., and Satoh, T. Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Arch. Biochem. Biophys., 277: 219-227, 1990.
10. Di Persio, L. P., Fontaine, R. N., and Hui, D. Y. Identification of the active site serine in pancreatic cholesterol esterase by chemical modification and site-specific mutagenesis. J. Biol. Chem., 265: 16801-16806, 1990.
11. Potter, P. M., Pawlik, C. A., Morion, C. L., Naeve, C. W., and Danks, M. K. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res., 58: 2646-2651, 1998.
12. Danks, M., Morton, C., Pawlik, C, and Potter, P. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res., 58: 20-22, 1998.
13. Rivory, L. P., and Robert, J. Reverse-phase high-performance liquid Chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. Biochem. Pharmacol., 661: 133-141,1994.
14. Tsuji, T., Kaneda, N., Kado, K., Yokokura, T., Yoshimoto, T., and Tsuru, D. CPT-11 converting enzyme from ral serum: purification and some properties. J. Pharmacobio-Dyn., 14: 341-349, 1991.
15. Martuza, R. L. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene wild type retrovirus kills other tumor cells. J. Neurosci. Res., 33: 493-503, 1992.
16. Gandia D., Abigerges, D., Armand, J. P., Chabot, G., Da Costa, L., De Forni, M., Mathieu-Boue, A., and Herait, P. CPT-11-induced cholinergic effects in cancer patients. J. Clin. Oncol., 11: 196-197, 1993.
17. Dilber, M. S., Abedi, M. R., Christensson, B., Bjorkstrand, B., Kidder, G. M., Naus, C. C., Gahrton, G., and Smith, C. I. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res., 57: 1523-1528, 1997.